"Remdesivir therapy in patients with COVID-19: A systematic review and " by Charan Thej Reddy Vegivinti, John M. Pederson et al.
 

Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

Document Type

Article

Publication Title

Annals of Medicine and Surgery

Abstract

Purpose: To perform a systematic review and meta-analysis of randomized controlled trials that examined remdesivir treatment for COVID-19. Materials and methods: A systematic literature search was performed using Pubmed, Embase, and ClinicalTrials.gov to identify studies published up to October 25, 2020 that examined COVID-19 treatment with remdesivir. A total of 3 randomized controlled trials that consisted of 1691 patients were included in the meta-analysis. Results: The odds for mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) following treatment was significantly lower in the remdesivir group compared to the control group (OR = 0.48 [95% CI: 0.34; 0.69], p < 0.001). The odds of early (at day 14/15; OR = 1.42 [95% CI: 1.16; 1.74], p < 0.001) and late (at day 28/29; OR = 1.44 [95% CI: 1.16; 1.79], p = 0.001) hospital discharge were significantly higher in the remdesivir group compared to the control group. There was no difference in the odds for mortality in patients treated with remdesivir (OR = 0.77 [95% CI: 0.56; 1.06], p = 0.108). Conclusions: Remdesivir attenuates disease progression, leading to lower odds of MV/ECMO and greater odds of hospital discharge for COVID-19 patients. However, remdesivir does not affect odds of mortality.

First Page

43

Last Page

48

DOI

10.1016/j.amsu.2020.12.051

Publication Date

2-1-2021

This document is currently not available here.

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 28
    • Policy Citations: 1
  • Usage
    • Abstract Views: 1
  • Captures
    • Readers: 97
  • Social Media
    • Shares, Likes & Comments: 11
see details

Share

COinS